Sign in
Taking peoplePhase 4

Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection

Key facts

Who runs it
Yongquan Shi
Where
China24 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
448 people, planned
Started
1 Oct 2026
Expected to end
30 May 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Linalarose Glutarate
  • Bismuth Quadruple Test
Record updated
27 October 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • (1) Adult patients aged 18-70 years, regardless of gender
  • (2) Patients diagnosed with Helicobacter pylori infection via 13C/14C-UBT
  • (3) Patients who have not previously undergone Helicobacter pylori eradication therapy
  • (4) Patients who have provided informed consent and voluntarily agreed to participate in this study

Who cannot take part

  • (6) Patients with concomitant peptic ulcers, reflux esophagitis, MALT lymphoma, gastrointestinal malignancies, or those who have undergone esophageal or gastric surgery
  • (9) Patients requiring treatment with atazanavir, nelfinavir, or rilpivirine
  • (1) Individuals allergic to the study drug
  • (4) Individuals with a history of failed Helicobacter pylori eradication therapy
  • (7) Patients with severe cardiac, hepatic, pulmonary, or renal diseases, or those with impaired immunity
  • (8) Patients unable to comply with treatment due to alcohol abuse, substance abuse, or severe mental illness
  • (2) Individuals who have taken antibiotics, bismuth-containing agents, probiotics, or traditional Chinese medicines with antibacterial activity within the past 4 weeks
  • (3) Individuals who have taken P-CAB, PPI, or H2 receptor antagonists within the past 2 weeks
  • (5) Women who are pregnant, breastfeeding, or planning to become pregnant

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aims to compare the efficacy of the dual therapy regimen of linralase glutarate capsules and amoxicillin versus the quadruple therapy regimen containing bismuth for the first-line eradication of Helicobacter pylori infection. The primary questions this trial aims to address include: 1. Whether the linalarenate glutarate capsule-amoxicillin dual-drug regimen is non-inferior to the bismuth-containing quadruple therapy, while simultaneously evaluating patient adherence and the incidence of adverse events in both treatment groups. Participants will: 1. Treatment group: Linaralate Glutarate Capsules (50 mg bid) + Amoxicillin (1 g tid), for a 14-day treatment course. 2. Control group: Esomeprazole 20 mg, twice daily (bid) + clarithromycin 0.5 g, twice daily (bid) + amoxicillin 1 g, twice daily (bid) + colloidal bismuth subcitrate 200 mg, twice daily (bid), for a 14-day treatment course. The primary endpoint is the Helicobacter pylori eradication rate 4 weeks after discontinuation of treatment.

The 2 groups in the trial

  • Treatment groupTreatment being tested

    Glutaric acid linalaric acid ester capsules (50 mg bid) + amoxicillin (1 g tid), for a 14-day course.

    Treatment: Linalarose Glutarate

  • Control groupExisting treatment, for comparison

    Esomeprazole 20 mg, twice daily (bid) + clarithromycin 0.5 g, twice daily (bid) + amoxicillin 1 g, twice daily (bid) + colloidal bismuth subcitrate 200 mg, twice daily (bid), for a 14-day treatment course.

    Treatment: Bismuth Quadruple Test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Controlled Study
Criteria questions
Built from NCT07897994, who can take part
Record updated
27 October 2026